vivoDART™ Assay

About vivoVerse

vivoVerse is an early-stage biotech company commercializing an AI-powered, whole-organism screening platform for toxicology and safety assessment. Its core technology, originating from academic research at The University of Texas at Austin, combines patented microfluidic chips (vivoChip), automated hardware (vivoScreen), and AI-driven image analysis to run high-throughput assays using C. elegans. The company's initial focus is on the vivoDART assay for developmental and reproductive toxicity, claiming it is 15x faster and 50x lower cost than mammalian assays, targeting industries like agrichemicals, pharmaceuticals, and petrochemicals to reduce animal testing and accelerate compound prioritization.

Therapeutic Areas